• News
  • SAN DIEGO
  • BioTech

Zohydro details timeframe for new Zohydro version

The San Diego drugmaker Zogenix says a harder-to-abuse version of its powerful painkiller Zohydro could be reviewed by regulators this fall and, if approved, might hit the market early next year.

The company said Wednesday that it recently met with Food and Drug Administration representatives, and it expects to submit an extended release, capsule version of Zohydro to the FDA by October.

The company also is working to develop a tablet version of the drug that maintains the medicine's extended-release properties even when it is crushed or chewed, which addresses one of the ways opioids are abused orally. The tablet also will have features that address abuse by injection or snorting.

Zogenix Inc. (Nasdaq: ZGNX) is aiming to apply for approval of this tablet version in the first half of 2016.

Zohydro has been a target of critics since it became the first single-ingredient hydrocodone drug ever approved for U.S. patients last fall. The pill contains up to five times more hydrocodone than Vicodin and sparks worry that it will add to the epidemic of opioid drug abuse that is blamed for thousands of overdose deaths annually.

Earlier this year, Zogenix said it created an oversight board of medical, addiction and law enforcement specialists to spot early signs of misuse using data from sources like prescribing statistics and addiction center reports. The drugmaker also announced that it was selling its migraine therapy business to focus on developing abuse-resistant forms of Zohydro.

Zogenix shares jumped more than 11 percent, or 22 cents, to $2.21 Wednesday in premarket trading. The stock price had dropped 42 percent so far this year, as of Tuesday's market close.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Zogenix Inc.

Company Website

12400 High Bluff Dr. Ste., 650
San Diego, CA 92130

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ZGNX
13.53
  -0.06  
- 0.44%
335,635,000
21.65
8.64

Zogenix Inc. Executive(s):

Roger Hawley

  • Chief Executive Officer

Stephen Farr

  • President

Ann Rhoads

  • Chief Financial Officer
Subscribe Today!